Share Prices & Company Research

Market News

24 Feb 2021 | 12:37

Icon to buy PRA Health Sciences in $12bn deal

(Sharecast News) - US outsourced drug and device developer Icon has agreed to buy PRA Health Sciences in a $12bn cash and stock deal.

The consideration represents a premium of about 30% to PRA's closing share price on Tuesday.

Icon said the deal "brings together two high-quality, innovative and growing organisations with similar cultures and a shared focus on high quality and efficient clinical trial execution from Phase 1 to post-approval studies".

The transaction is expected to deliver double-digit accretion in the first full year and grow to 20%+ thereafter, Icon said, driven by growth momentum, estimated annual run-rate cost synergies of $150m, and the combined effective tax rate decreasing to 14%, both to be realised in approximately four years.

Icon's chief executive officer, Dr. Steve Cutler, said: "The combined company will create a new paradigm for accelerating clinical research and bringing new medicines and devices to market. Both Icon and PRA have track records of robust growth and performance and we are ready to build on this unrivalled position of strength, utilising the outstanding talent in both organisations.

"With broader and deeper operational scale combined with innovative technology and real world data solutions, we will enable all customers to reduce their development time and cost. We will be the leading provider of de-centralised and hybrid trial solutions through the integration of our data capabilities, health platforms and Accellacare site network."

News of the deal came alongside Icon's fourth-quarter and full-year 2020 results.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.